Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

http://www.wikidata.org/entity/Q34171999

about

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches Oral Mucositis Induced By Anticancer Therapies Improving the efficacy of chemoradiation with targeted agents Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer The role of systemic treatment before, during, and after definitive treatment p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma An update on larynx cancer Molecular Aspects of Head and Neck Cancer Therapy Management of Oropharyngeal Cancer in the HPV Era.Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma.RGD-Binding Integrins in Head and Neck Cancers.Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234 EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure.Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group.Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.Heterogeneity of (18)F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma.Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients.Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis Personalized radiotherapy: concepts, biomarkers and trial design Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

P2860

Q24187274-4DB6E4E2-A1FD-42C3-A1B6-5D394C543AAE Q26750719-0A02981E-01D1-45EA-BC18-FA0A403D561C Q26752584-52BB731E-DB32-4020-9F5A-7CD6A5CFF3CB Q26767046-FCC5C0D8-CAAA-41E2-96E6-A11A4FCCE615 Q26777493-04BACD86-A592-467B-8752-D8D430AF3EA6 Q26850193-26ACB985-1F49-49FA-A3E5-5D739AA968ED Q26852215-E85C6C68-B54E-42AD-BD37-C192CD8CB1BD Q26859285-9A43C7B2-50BE-4E16-98A8-953E8C23C601 Q27853077-C2AF2966-0995-4E15-A28A-AD4084197099 Q27853245-BAC91A36-17B1-4C9E-954D-99A880E6CA3B Q28071998-465DD462-A334-4A28-9661-09C0ECA865D1 Q28079132-5B09DA5E-2417-443F-B332-50C4CB4DB1C9 Q28082815-96842D08-1707-435C-A9BF-EAE49D98BBF9 Q30248326-783D9725-E3AE-458A-A590-6AD32381BA28 Q30313175-4613CFF7-DAE8-4CCC-B524-B9E62FA1178A Q33426350-C8FAFE34-39CC-452A-8119-3B300247CBB2 Q33682966-C431004C-75B2-44AC-8C22-7D6D81315B5E Q33820511-6ACF9EF4-848E-4F03-B25A-688B41963D4E Q33832735-59E658EF-B41C-403E-BA6E-710B2132A5D4 Q34000997-96179778-5615-4032-B44C-4B29A1D6079C Q34216725-0AD4C606-8779-4607-A6AE-82CC716EFCF9 Q34287666-57938AE5-E671-4B3D-A454-A81E44FC3606 Q35019239-C405C569-51A0-43B3-934D-72EB955F8713 Q35030236-8A416AFB-4573-4F8E-AD8B-DC4D28990E26 Q35191014-FF38A5B6-9919-4D53-ADBC-D80A98D071F5 Q35534813-28A6C9D2-670B-447F-BEDF-8D8E95C1B30E Q35611873-6B7FD7C8-D970-49A0-AF64-B6F88ADF41B6 Q35688621-A42BD93A-DB41-4E9F-8F2D-48B4480F4150 Q35693308-515D1AA5-AFD8-49ED-83F6-AA5A271D627F Q35751948-841F59BA-5BF4-482C-9572-AE3953824449 Q35756750-EDE330B9-0D6E-40E9-91FE-F6824899F401 Q35803714-534F3F83-5270-44CC-A0B5-DB1FC22500A1 Q35966191-0E29E083-6EC6-4147-880B-82C738576552 Q36030906-167E8D8E-99F5-4FA0-B561-83A6A0B8E0AF Q36102873-3B013B43-50C4-43C5-B698-79669CD54E0D Q36114633-2D6839A1-D775-4047-BDD4-BA65699F6A4B Q36235704-C2FC7C2F-BCA5-4E4E-863F-ABEC026E1633 Q36238876-7310C052-7E11-4D3D-97FC-6F281173AC77 Q36244369-612A8678-272E-4B4A-BE2A-FA2CF8537E13 Q36303845-573A030D-DCD0-475A-92B4-E424F27A9483

P2860

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

http://www.wikidata.org/entity/Q34171999

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@ast

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@en

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@nl

type

label

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@ast

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@en

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@nl

prefLabel

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@ast

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@en

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522.

@nl

P1433

Q34171999-F63575A7-DB87-4F6C-AB24-3FC33B3B935C

P1476

Q34171999-46FD8D67-8843-43CD-8E7A-385628A7B01E

P2093

Q34171999-02242B3A-8058-47B3-958F-DCBA25D66D8E

Q34171999-06FF4CA2-00D6-43E5-9E04-F95EE50BF54F

Q34171999-0D0948B7-6E2A-41FE-8DF6-E9EF289ADA0C

Q34171999-1F4EBB7B-A82F-4120-8394-DD290337E313

Q34171999-28D2B7F7-B66C-4162-BE0A-1F6602983579

Q34171999-3C23790E-44C3-43C2-8DB1-BF837E7B2FBC

Q34171999-52F8AFF1-3AF0-4106-8E85-8C33085A8CA5

Q34171999-5775A7ED-8193-4DAC-9572-F7C28C563170

Q34171999-5B00EC3E-0225-445B-80BE-26477E162155

Q34171999-5EFB1094-759B-4400-834B-1B8668EE5FD7

P2860

Q34171999-0F41435A-3674-4E69-B240-14C9140D268C

Q34171999-2DF27C75-BBE4-4C00-874C-EA22DCEE1B3F

Q34171999-3D2008C7-871F-4D19-A627-1ED866BA2461

Q34171999-3DB7EB67-9F65-4B7F-BA30-A230B82C2C97

Q34171999-4064E614-C5C9-4A2D-9AF8-A7B5D6EA0584

Q34171999-44639582-EBBB-4838-B5BA-3CFEA31B17E4

Q34171999-479FDD9B-8BA6-4210-B231-A1C410344610

Q34171999-4E609D3A-82A7-43F8-B7BD-DD02862699DE

Q34171999-4F29DF0E-0FAB-439B-AE93-BA3CCED7564B

Q34171999-55A0966A-1C88-4EDF-ABE6-47AA93333919

P304

Q34171999-17689697-B8E7-47F4-852D-DC77E1413759

P31

Q34171999-14CFE7D2-2512-42D4-B42A-BD17BF4BB4C5

P356

Q34171999-56C9AF98-80F1-43BC-A887-E323AB8505A5

P407

Q34171999-878BCAE0-221D-4D6A-95F6-39219A0DDE9C

P433

Q34171999-38F20197-AB8A-462D-93F0-567F26DC4F44

P478

Q34171999-06949431-6879-49C5-80CB-4E58114E8AB7

P50

Q34171999-2DBB5205-C21E-4FC6-A078-CD5368CE2C8F

Q34171999-4A12252F-6C4F-4E9B-A782-4F85CF64D416

P577

Q34171999-32C909B6-D9FD-4C3A-868A-92C7E3575CCE

P698

Q34171999-60514D2A-28C9-46FA-A8C1-0AD354F3334C

P921

Q34171999-5B7FCFED-71DA-405A-8431-F7AB13775714

Q34171999-8CFFFA74-A94E-44BA-B0AA-910965B7B178

P932

Q34171999-F6CCFD0C-85DF-42EC-A6A8-112834804E25

P356

JCO.2013.53.5633

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... and neck carcinoma: RTOG 0522

@en

P2093

Adam S Garden

http://www.w3.org/2001/XMLSchema#string

Adel K El-Naggar

http://www.w3.org/2001/XMLSchema#string

Andre A Konski

http://www.w3.org/2001/XMLSchema#string

Andy Trotti

http://www.w3.org/2001/XMLSchema#string

Eric J Sherman

http://www.w3.org/2001/XMLSchema#string

James A Bonner

http://www.w3.org/2001/XMLSchema#string

James M Galvin

http://www.w3.org/2001/XMLSchema#string

Jonathan Harris

http://www.w3.org/2001/XMLSchema#string

Jonathan J Beitler

http://www.w3.org/2001/XMLSchema#string

K Kian Ang

http://www.w3.org/2001/XMLSchema#string

P2860

Human papillomavirus and survival of patients with oropharyngeal cancer.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Evaluation of survival data and two new rank order statistics arising in its consideration.

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma.

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis

P304

2940-2950

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.53.5633

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

David I Rosenthal

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25154822

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4162493

http://www.w3.org/2001/XMLSchema#string